Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark, with preliminary imaging data showing encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, which the company believes could enhance development of MS therapies including its investigational candidate Lucid-MS, for which an IND submission for a Phase 2 trial was submitted to the FDA in March 2026.
This milestone is significant because it brings the study closer to validating a non-invasive method to visualize myelin damage in real time. Direct imaging of demyelination has been a long-standing challenge in multiple sclerosis research, as standard MRI scans lack specificity for myelin. If successful, the [¹⁸F]3F4AP tracer could become a critical tool for diagnosing MS, monitoring disease progression, and evaluating the efficacy of new therapies. For Quantum BioPharma, the study supports the development of Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation—the underlying mechanism of multiple sclerosis.
The implications for the MS treatment landscape are substantial. Currently, most MS therapies focus on modulating the immune system to reduce inflammation, but they do not directly repair myelin. Lucid-MS aims to fill this gap by promoting remyelination, potentially offering a disease-modifying approach that could restore neurological function. The Phase 2 IND submission in March 2026 signals that Quantum is moving closer to clinical trials in humans. Positive results from the imaging study could accelerate regulatory discussions and investor interest, as a validated biomarker for myelin repair would be a major asset for the entire field.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on Lucid-MS. The company also retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd Wellness Inc., which markets UNBUZZD(TM), and receives royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains full rights to develop pharmaceutical and medical uses of similar products.
For leaders in business and technology, this development underscores the convergence of advanced imaging and neurodegenerative disease therapeutics. The ability to directly visualize demyelination could transform clinical trials by providing a more objective endpoint, reducing trial durations and costs. It also opens avenues for AI-driven analysis of PET imaging data, potentially improving diagnostic accuracy and treatment personalization. As Quantum progresses, stakeholders should monitor the completion of the imaging study and the initiation of the Phase 2 trial for Lucid-MS, as these events could set new standards in MS care.
Forward-looking statements in this article involve risks and uncertainties. For more information, see the full press release here and the company's newsroom here.
